1. Home
  2. CVKD vs CHNR Comparison

CVKD vs CHNR Comparison

Compare CVKD & CHNR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • CVKD
  • CHNR
  • Stock Information
  • Founded
  • CVKD 2022
  • CHNR N/A
  • Country
  • CVKD United States
  • CHNR Hong Kong
  • Employees
  • CVKD N/A
  • CHNR N/A
  • Industry
  • CVKD Medicinal Chemicals and Botanical Products
  • CHNR Precious Metals
  • Sector
  • CVKD Health Care
  • CHNR Basic Materials
  • Exchange
  • CVKD Nasdaq
  • CHNR Nasdaq
  • Market Cap
  • CVKD 8.2M
  • CHNR 8.6M
  • IPO Year
  • CVKD 2023
  • CHNR 1995
  • Fundamental
  • Price
  • CVKD $0.43
  • CHNR $0.77
  • Analyst Decision
  • CVKD Strong Buy
  • CHNR
  • Analyst Count
  • CVKD 2
  • CHNR 0
  • Target Price
  • CVKD $3.50
  • CHNR N/A
  • AVG Volume (30 Days)
  • CVKD 71.0K
  • CHNR 722.4K
  • Earning Date
  • CVKD 08-12-2024
  • CHNR 05-16-2023
  • Dividend Yield
  • CVKD N/A
  • CHNR N/A
  • EPS Growth
  • CVKD N/A
  • CHNR N/A
  • EPS
  • CVKD N/A
  • CHNR N/A
  • Revenue
  • CVKD N/A
  • CHNR N/A
  • Revenue This Year
  • CVKD N/A
  • CHNR N/A
  • Revenue Next Year
  • CVKD N/A
  • CHNR N/A
  • P/E Ratio
  • CVKD N/A
  • CHNR N/A
  • Revenue Growth
  • CVKD N/A
  • CHNR N/A
  • 52 Week Low
  • CVKD $0.36
  • CHNR $0.61
  • 52 Week High
  • CVKD $2.17
  • CHNR $8.85
  • Technical
  • Relative Strength Index (RSI)
  • CVKD 41.09
  • CHNR 47.47
  • Support Level
  • CVKD $0.43
  • CHNR $0.71
  • Resistance Level
  • CVKD $0.49
  • CHNR $0.81
  • Average True Range (ATR)
  • CVKD 0.02
  • CHNR 0.07
  • MACD
  • CVKD -0.00
  • CHNR 0.01
  • Stochastic Oscillator
  • CVKD 6.67
  • CHNR 49.68

About CVKD Cadrenal Therapeutics Inc.

Cadrenal Therapeutics Inc is focused on developing a novel therapy with orphan drug indication, tecarfarin, for the prevention of systemic thromboembolism (blood clots) of cardiac origin in patients with end-stage renal disease (on dialysis) and atrial fibrillation (irregular heartbeat) or AFib. Tecarfarin is an anticoagulant designed using a drug design process that targets a different pathway than most commonly prescribed drugs for the treatment of thrombosis and AFib.

About CHNR China Natural Resources Inc.

China Natural Resources Inc is an investment holding company. It principally engaged in the exploration and mining and wastewater treatment businesses in the People's Republic of China. The company has two operating segments: (i) Wastewater treatment segment, which consists of sales of assembled equipment, provision of construction service, and participation in PPP projects as an operator (ii) Exploration and mining segment, which consists of the exploration of lead, silver, and other metals in the Inner Mongolia Autonomous Region of the PRC and the trading of copper ores products. It earns the majority of its revenue from the Wastewater treatment segment.

Share on Social Networks: